Skip to main content

Table 5 Differences in protein levels between p-tau subgroups in amyloid-negative CN individuals

From: P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles

Protein (n) Protein level per group: estimate ± standard error of the mean (SE) Differences between p-tau subgroups: mean ± SE p-values of contrasts
Subgroup 1: p-tau ≤ 56 pg/ml (n = 103) Subgroup 2: p-tau 57–96 pg/ml (n = 7) Subgroup 3: p-tau 97–159 pg/ml (n = 2) 2 vs 1 3 vs 1 3 vs 2 2 vs 1 3 vs 1 3 vs 2
Core AD biomarker
 Aβ42 (n = 112) 0.04 ± 0.11 0.61 ± 0.39 − 0.01 ± 0.74 0.56 ± 0.41 − 0.05 ± 0.74 − 0.62 ± 0.83 0.427 1.000 0.843
Analytes
 BACE1 (n = 112) 0.03 ± 0.1 1.44 ± 0.37 2.71 ± 0.69 1.4 ± 0.38 2.68 ± 0.69 1.28 ± 0.78 1.02E−03 5.61E−04 0.276
 Aβ40 (n = 112) 0.1 ± 0.1 1.55 ± 0.36 2.3 ± 0.69 1.45 ± 0.38 2.2 ± 0.69 0.75 ± 0.77 6.24E−04 5.54E−03 0.701
 NfL (n = 111) − 0.07 ± 0.09 0.36 ± 0.31 0.34 ± 0.59 0.42 ± 0.32 0.41 ± 0.59 − 0.02 ± 0.66 0.470 0.869 1.000
 VAMP2 (n = 105) 0.07 ± 0.11 1.4 ± 0.38 2.3 ± 0.72 1.33 ± 0.39 2.23 ± 0.72 0.9 ± 0.8 3.16E−03 7.51E−03 0.604
 NRGN (n = 112) 0.09 ± 0.1 1.37 ± 0.38 2.88 ± 0.71 1.29 ± 0.39 2.79 ± 0.72 1.5 ± 0.8 4.25E−03 5.29E−04 0.180
  1. Protein levels were natural log-transformed and standardized relative to cognitively normal individuals with normal CSF amyloid, t-tau, and p-tau (controls). Estimates of protein level differences between p-tau subgroups are corrected for age and sex. p-values of comparisons between p-tau subgroups were adjusted with the Sidak method (considered significant at p-value < 0.05)
  2. CN, cognitively normal; CSF, cerebrospinal fluid; BACE1, beta-site amyloid precursor protein cleaving enzyme 1; Aβ42, amyloid-beta 1–42; Aβ40, amyloid-beta 1–40; NfL, neurofilament light; NRGN, neurogranin; VAMP2, vesicle-associated membrane protein 2